Dompé On A Roll After Securing A “Yes” Under The UK’s Early Access Scheme
Executive Summary
Just weeks after the European Medicines Agency recommended that Dompé’s neurotrophic keratitis treatment Oxervate be authorized for sale, the company has received the all clear to make the product available to patients in the UK before its formal approval by the European Commission. Meanwhile, the Italian company is working on targeting the US and Japanese markets too.